Stada And Xbrane Gain EU All-Clear For Ranibizumab Biosimilar
Companies Aim To Launch Lucentis Rival In Selected European Markets Early Next Year
The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.
